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Cost-Effectiveness Analysis of a Silver-Coated Endotracheal Tube
to Reduce the Incidence of Ventilator-Associated Pneumonia
Andrew F. Shorr, MD, MPH; Marya D. Zilberberg, MD, MPH; Marin Kollef, MD

objective. To conduct a cost-effectiveness analysis of the economic outcomes of ventilator-associated pneumonia (VAP) prevention
associated with silver-coated endotracheal tubes versus uncoated endotracheal tubes.
design. We used a simple decision model based on a hypothetical 1,000-patient cohort intubated with silver-coated or uncoated
endotracheal tubes. The primary end point was marginal hospital savings per case of VAP prevented (savings from using silver-coated
endotracheal tubes minus acquisition cost divided by number of VAP cases prevented).
methods. We followed each branch of the decision model to VAP or no VAP and conducted Monte Carlo simulations and sensitivity
analyses. Inputs for VAP incidence, relative risk reduction, and hospital costs were derived from publicly available sources. Relative risk
reduction was derived from the pivotal study of the silver-coated endotracheal tube.
results. In the base-case analysis, we reduced the pivotal study relative risk in incidence of microbiologically confirmed VAP in patients
intubated x24 hours from 35.9% to 24%. Thus, 23 of 97 expected cases of VAP could be prevented with silver-coated endotracheal tubes.
The savings per case of VAP prevented was $12,840 in the base case, with assumed marginal VAP cost of $16,620 and costs of $90.00 for
coated and $2.00 for uncoated endotracheal tubes. Estimates were most sensitive to assumptions regarding VAP cost and relative risk
reduction with silver-coated endotracheal tubes. Nonetheless, in multivariate sensitivity analyses, the silver-coated endotracheal tubes yielded
persistent savings (95% confidence interval, $9,630–$16,356) per case of VAP prevented. With other base-case inputs held constant, breakeven cost for silver-coated endotracheal tubes was $388.
conclusions.

The silver-coated endotracheal tube represents a strategy for preventing VAP that may yield hospital savings.
Infect Control Hosp Epidemiol 2009; 30:759-763

Ventilator-associated pneumonia (VAP) places a substantial
burden on healthcare systems because of its frequency and
associated morbidity and hospital costs. VAP occurs at a rate
of 2.5–12.3 episodes per 1,000 ventilator days1 and occurs in
9.3%–23.5% of patients receiving mechanical ventilation.2-5
VAP adds 5–7 days to the length of stay in the intensive care
unit (ICU)4 and 10–12 days to the length of hospitalization.2,3
Specifically, estimates of attributable hospital costs for VAP
range from $10,000 to $25,000.3-6 Because of its high clinical
and economic burden, VAP is now a focus of efforts to improve
outcomes and patient safety in the ICU. These efforts will
become more pertinent if the Centers for Medicare and Medicaid Services adds VAP to the list of conditions that will no
longer be eligible for incremental payments.
A silver-coated endotracheal tube (Agento I. C., C. R. Bard)
has been developed to reduce VAP incidence. The silver coating provides broad-spectrum antimicrobial activity,7 reduces
bacterial adhesion to the endotracheal tube,8,9 and blocks biofilm formation on the endotracheal tube.10 The silver ions are

microdispersed in a proprietary polymer that may enhance
antimicrobial activity by blocking bacterial adhesion to the
endotracheal tube.11-14 The North American Silver-Coated Endotracheal Tube (NASCENT) study15 provided clinical evidence of efficacy in 2,003 patients expected to require mechanical ventilation for x24 hours. In this randomized,
controlled, pivotal trial, the silver-coated endotracheal tube
resulted in a 35.9% relative risk reduction of VAP (P p .03),
with a cumulative incidence of microbiologically confirmed
VAP of 7.5% in patients managed with uncoated endotracheal
tubes and 4.8% in patients managed with silver-coated endotracheal tubes. Therefore, the estimated number of patients
that must be treated with the silver-coated endotracheal tube
to prevent 1 case of VAP is approximately 37 based on the
2.7% absolute risk reduction in patients intubated for x24
hours.
We hypothesized that use of silver-coated endotracheal
tubes would be cost effective in patients requiring mechanical
ventilation for x24 hours. Given the economic burden as-

From Washington Hospital Center, Washington, DC (A.F.S.); EviMed Research Group, LLC, Goshen, MA (M.D.Z.); and Washington University School
of Medicine, St. Louis, MO (M.K.)
Received December 5, 2008; accepted March 6, 2009; electronically published June 19, 2009.
䉷 2009 by The Society for Healthcare Epidemiology of America. All rights reserved. 0899-823X/2009/3008-0007$15.00. DOI: 10.1086/599005

760

infection control and hospital epidemiology

august 2009, vol. 30, no. 8

sociated with VAP,2-5 routine use of an endotracheal tube
capable of reducing the incidence of VAP might offset the
acquisition cost of the device, resulting in savings to the hospital. To test this hypothesis, we developed a decision model
to compare the costs of silver-coated and uncoated endotracheal tubes relative to those associated with the development
of VAP.

methods
We compared economic outcomes in terms of VAP prevention with the use of silver-coated endotracheal tubes to outcomes with the use of uncoated endotracheal tubes in a hypothetical cohort of 1,000 patients expected to require
mechanical ventilation for x24 hours. The primary end point
was marginal hospital savings associated with prevention of
1 case of VAP, and it was calculated as savings in VAP hospital
costs associated with use of the silver-coated endotracheal
tube minus direct hospital acquisition cost of the endotracheal
tube divided by the number of VAP cases prevented. This
ratio represented the cost (or savings) per 1 case of VAP
prevented. The secondary end point was marginal hospital
savings (or costs) associated with reduced incidence of VAP
over the entire 1,000-patient cohort. We followed the recommendations of the Panel on Cost-Effectiveness in Health
and Medicine.16
Model structure and inputs. We used a simple decision
tree to model the outcomes. The only decision node represented the determination to use silver-coated or uncoated
endotracheal tubes. We passed the 1,000-patient cohort
through each branch of the decision tree separately to development of VAP or no development of VAP. The model
required the following inputs: incidence of VAP, relative risk
reduction of VAP with silver-coated endotracheal tube, hospital costs associated with VAP, and costs of silver-coated and
uncoated endotracheal tubes (Table 1). We used the medical
care component of the Consumer Price Index17 to adjust the
estimated cost of VAP to 2007 US dollars.
Monte Carlo simulations and sensitivity analyses. We performed Monte Carlo simulations and sensitivity analyses to
identify important model uncertainties and to assess the robustness of our findings across the wide range of VAP incidence in different patient populations. Each outcome was
tested in 10,000 simulation trials, while the estimates were

simultaneously and randomly varied across the ranges specified in Table 1. The ranges for the incidence of VAP4 and
hospital cost of VAP5 were bound by their corresponding
published 95% confidence intervals. We varied the relative
risk reduction of VAP by Ⳳ50% and the cost estimate of the
silver-coated endotracheal tube by Ⳳ$10. To bias the model
against the silver-coated endotracheal tube, we set the lower
bound of the acquisition cost for the uncoated endotracheal
tube at $0.00. We conducted sensitivity analyses to assess the
univariate contribution of uncertainty in each model parameter to the variability in outcomes and subsequently completed a 2-way sensitivity analysis—simultaneously varying
the 2 most influential inputs on the outcome estimate. We
also tested break-even scenarios to determine circumstances
under which each input was no longer associated with hospital savings and a worst-case scenario with all inputs maximally biased against the silver-coated endotracheal tube.

results
In the base-case analysis, we estimated that use of silvercoated endotracheal tubes would prevent 23 of 97 expected
cases of VAP. Despite the higher acquisition cost of the silvercoated endotracheal tube, we calculated a marginal hospital
savings of $12,840 per 1 case of VAP prevented, with assumed
marginal VAP cost of $16,620 (in 2007 US dollars) and costs
of $90.00 for silver-coated and $2.00 for uncoated endotracheal tubes. This translated to a total annualized marginal
hospital savings of $298,914 for the entire 1,000-patient cohort, reducing VAP-specific hospital costs by 18.5%.
In the univariate sensitivity analysis, the model was most
sensitive to VAP hospital cost, VAP relative risk reduction
associated with the silver-coated endotracheal tube, and
pooled cumulative risk of VAP assumptions (Figure). Varying
the hospital cost of VAP across the 95% confidence interval
led to less than 25% variability in the point estimate for
savings with the silver-coated endotracheal tube. Similarly,
varying the relative risk reduction across the prespecified
range of 12%–36% led to less than 25% variability in savings
with the silver-coated endotracheal tube. The model was relatively insensitive to the acquisition costs of the silver-coated
and the uncoated endotracheal tubes.
In a 2-way sensitivity analysis of the most influential inputs,
use of the silver-coated endotracheal tube continued to yield

table 1. Model Input Estimates and Sources
Input variable
Pooled cumulative VAP risk with uncoated endotracheal tube
VAP relative risk reduction with silver-coated endotracheal tubea
Marginal VAP hospital costsb
Silver-coated endotracheal tube cost
Uncoated endotracheal tube cost
note.
a
b

Point estimate

Range tested

Source

9.7%
24%
$16,620
$90.00
$2.00

7.0%–12.5%
12%–36%
$7,355–$36,621
$80.00–$100.00
$0.00–$5.00

Safdar et al4
Kollef et al15
Warren et al5
Assumption
Expert opinion

VAP, ventilator-associated pneumonia.
Actual relative risk reduction of 36% seen in the NASCENT study15 reduced by 33% to 24% in the base case.
Reported values adjusted to 2007 US dollars.5

silver-coated endotracheal tube
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In the worst-case scenario with each input maximally
skewed against the silver-coated endotracheal tube, the hospital cost to prevent 1 case of VAP was $4,550, with assumed
VAP risk of only 7%, relative VAP risk reduction of 12%,
marginal VAP cost of $7,355, and cost of $100 for the silvercoated endotracheal tube. In the worst-case scenario, the uncoated endotracheal tubes had to be free (cost of $0.00).

discussion

figure.
Hospital savings per 1 case of ventilator-associated
pneumonia (VAP) prevented. The vertical line represents the savings
in the base-case scenario. The horizontal bars represent the range
in hospital savings associated with varying each input between the
upper and lower limits while holding other variables constant.

hospital savings (Table 2). For example, diminishing the cost
of VAP from the base case to $7,355 yielded a persistently
favorable profile for the silver-coated endotracheal tube with
cost savings of $3,575 per 1 case of VAP prevented. Similarly,
lowering the magnitude of VAP relative risk reduction from
the base case of 24% to 12% resulted in hospital savings of
$9,060 per 1 case of VAP prevented.
In a multivariate Monte Carlo simulation involving 10,000
trials for each outcome, the 95% confidence interval for the
point estimate was $9,630–$16,356 saved per 1 case of VAP
prevented. This translated to a 95% confidence interval of
$195,104–$424,809 in savings for the entire 1,000-patient
cohort.
In the break-even sensitivity analysis, the cost of the silvercoated endotracheal tube had to be increased to $388 to offset
the savings when all other inputs were held constant at the
base-case point estimates. In break-even sensitivity analyses
of other inputs, VAP risk had to be decreased from 9.7% to
2.2%, relative VAP risk reduction with the silver-coated endotracheal tube had to decrease from 24% to 5.5%, or marginal VAP cost had to decline from $16,620 to $3,780 to offset
the savings when all other inputs were held constant.

Our findings demonstrated the cost effectiveness of a silvercoated endotracheal tube designed to reduce VAP incidence.
Although the acquisition cost of the silver-coated endotracheal tube far exceeds that of an uncoated endotracheal tube,
this difference in cost was offset by the excess hospital costs
associated with VAP infection.3-6 Specifically, the marginal
hospital savings per 1 case of VAP prevented was $12,840,
confirming that the silver-coated endotracheal tube was associated with substantial savings. Despite uncertainty associated with specific model inputs, our conclusions regarding
the cost implications of the silver-coated endotracheal tube
remained valid across a wide range of assumptions.
In accordance with published recommendations,16 we intentionally biased model assumptions to favor uncoated endotracheal tubes. For example, we diminished the relative
risk reduction observed in the NASCENT study15 by onethird. We did this to simulate actual practice, where the effect
size is often smaller than what is reported in controlled clinical studies that (by design) try to limit variability through
precise entry criteria. Consistent with our conservative approach, we also chose the estimate for incidence of VAP from
a meta-analysis of 38 prospective cohort or nonrandomized
studies of 48,112 patients.4 The pooled cumulative incidence
of VAP in that population was 9.7%, which approximated
the incidence in a large US database.2 Similarly, our marginal
hospital cost of VAP was based on a conservative estimate of
approximately $12,000,5 which was within the range of attributable costs calculated in the meta-analysis.4 Higher values
have been reported for both VAP incidence and VAP hospital
cost.3,6 Of course, use of these higher inputs would have made
the intervention even more cost effective.
We performed extensive sensitivity testing to capture the
substantial uncertainty surrounding model inputs and the

table 2. Marginal hospital savings per 1 case of VAP prevented with use of
silver-coated endotracheal tube in a 2-way sensitivity analysis
Cost of VAP
per case, US$
7,355
11,988
16,620
26,621
36,621
note.

Marginal hospital savings, US$
12% RRR

18% RRR

24% RRR

30% RRR

36% RRR

⫺205
4,428
9,060
19,061
29,061

2,315
6,948
11,580
21,581
31,581

3,575
8,208
12,840
22,841
32,841

4,331
8,964
13,596
23,597
33,597

4,835
9,468
14,100
24,101
34,101

RRR, relative risk reduction; VAP, ventilator-associated pneumonia.
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unique costs and epidemiologic situations of individual institutions. For example, VAP risk is difficult to estimate because accurate diagnosis is confounded by other frequent ICU
complications that mimic the clinical appearance of VAP.18
Consequently, clinical criteria can lead to inaccurate diagnosis
and overestimation of the incidence, whereas the microbiologic criteria used in the NASCENT study15 are not likely to
be associated with this limitation. Each of our sensitivity analyses confirmed the robustness of the hospital savings associated with the silver-coated endotracheal tube over a wide
range for each model input. The most influential input on
the outcome estimate was marginal hospital cost of VAP. Diminishing this input to its lower 95% confidence bound,5
however, did not alter the principal finding. Only the extreme
scenario of lowest VAP cost combined with lowest VAP relative risk reduction failed to yield savings. Nonetheless, the
additional expenditures required for use of the silver-coated
endotracheal tube were modest and totaled only $205 to prevent 1 case of VAP.
The marginal hospital savings associated with use of the
silver-coated endotracheal tube was at least comparable to
that of other prevention strategies generally employed in the
ICU and to that of specific VAP prevention strategies. For
example, continuous subglottic suctioning saves $1,924 per
case of VAP prevented.19 An infection control strategy comprising intensive surveillance and interventions saves approximately $5,300 per case.20 Oral decontamination with
various antibiotic preparations saves $13,430 per case.21 In
contrast with other prevention strategies, the use of the silvercoated endotracheal tube was supported by data from a large
prospective randomized trial, whereas the quality of the data
supporting these alternative strategies is more limited.
Successful implementation of prevention strategies typically requires a multidisciplinary team,22 staff education,23,24
and adequate staffing levels,25 all followed by continuous vigilance and surveillance to maintain success.26 Unfortunately,
nonadherence is common among both physicians27 and
nurses,28 suggesting a practical advantage for use of the silvercoated endotracheal tube. Because its efficacy does not rely
on behavioral changes by healthcare providers or procedural
changes within the ICU, the silver-coated endotracheal tube
becomes user independent after placement. This in turn removes an important component of process of care from the
patient safety equation and is consistent with efforts to alter
culture in the ICU.
Our pharmacoeconomic analysis had several limitations.
First, only 1 clinical study was used to estimate relative risk
reduction of VAP with use of silver-coated endotracheal tubes;
however, the NASCENT study15 was the largest randomized
study of the impact of an endotracheal tube on incidence of
VAP. Use of the silver-coated endotracheal tube was not associated with decreased length of hospital stay in the NASCENT study.15 Failure to detect between-group differences in
length of stay, one of the most important drivers of economic
outcome, is not surprising in view of the low incidence of

microbiologically confirmed VAP. Furthermore, the pivotal
study was not powered to detect between-group differences
in secondary end points.
Second, the model assumed that all types of VAP have
similar financial implications. In other words, the costs of
VAP due to Pseudomonas aeruginosa may not be the same as
those due to methicillin-susceptible Staphylococcus aureus. To
address this, we altered the cost estimates for VAP extensively
and found that the hospital savings persisted. Similarly, the
model did not differentiate between early- and late-onset VAP,
which also may have different financial implications. In clinical practice, however, most cases of VAP occur during the
first 7–8 days of intubation because the median duration of
intubation is less than 10 days29 and more than 75% of tubes
are removed before 10 days.30,31
Third, we quantified cost effectiveness from the hospital
perspective. Modeling from the societal perspective would not
necessarily have diminished the cost effectiveness of the silvercoated endotracheal tube because it is unclear whether VAP
is associated with attributable mortality. In fact, consideration
of long-term, patient-reported complications of VAP probably would have augmented our findings.
Finally, there are likely hidden costs that we could not
consider. Conversely, there are potential savings that we could
not specifically model. For example, decreased VAP rates may
help prevent the spread of antimicrobial resistance. From the
throughput perspective, preventing VAP may facilitate bed
turnover in the ICU and thus help eliminate bottlenecks that
impede access to appropriate care.
Our pharmacoeconomic findings, combined with previous
data demonstrating clinical benefit, indicated that use of a
silver-coated endotracheal tube represents a strategy for preventing VAP that may result in savings to the hospital or
healthcare system. Importantly, the silver-coated endotracheal
tube becomes user independent after intubation and does not
add to the burden of the healthcare provider. Collectively,
these findings suggested that routine use of the silver-coated
endotracheal tube among patients expected to require mechanical ventilation for x24 hours could have important
public health implications.
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